A convergence of market forces will push life sciences employers to rethink their workforce strategies and reimagine how work ...

In the AI era, thriving life sciences organizations will differentiate themselves based on their ability to combine AIs power ...

Royalty-bearing license agreements are a cornerstone of commercialization in the life sciences and technology industries. Companies often use them to expand their business into new markets while ...

What does strategy look like for a drug development program? The word strategy can mean different things to different individuals. If you polled a group on a development team, you may receive ...

“THAT WAS A TERRIFYING MOMENT,” reflects Matt Patterson, cofounder, chairman, and CEO of Audentes Therapeutics, a genetic medicines company focused on the adeno-associated virus (AAV). It was the fall ...

As biotech companies face decreasing productivity, they need ways to do more with less, and fast. A fresh approach to achieve this is by rethinking how innovation is structured: collaborate early and ...

Recently, there has been heightened focus on dual brand approaches in which the same molecule is approved for multiple indications and packaged, priced, and distributed under different brand names.

Why did John Oyler, an American entrepreneur, decide to build a global biopharmaceutical company with roots in China? Ask the chairman, cofounder, and CEO of BeiGene that question and you’re going to ...

As pharmaceutical manufacturers grow, they often pursue external sources of innovation to supplement their own R&D efforts. A recent study found that 45% of drugs in the pipelines of 20 large ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

Sometimes it’s difficult to separate the identity of a company from that of its CEO. For example, when we think of Amazon and Microsoft, we naturally think of Jeff Bezos and Bill Gates. In the ...

A substantial share of biopharmaceutical drug launches (>50%) fail to meet their projected analyst forecasts (see also Simon-Kucher Biotech industry study 2019). With considerable investment going ...